The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Unanswered questions in aggressive B-cell lymphoma
Mark Roschewski, MD, NCI Center for Cancer Research, Bethesda, MD, discusses unanswered questions in aggressive B-cell lymphoma, including using immunotherapy in the frontline setting, selecting subtypes of patients that benefit from certain agents, eradicating chemotherapy, and defining remission. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
